StreetInsider.com News Articles

Form 4 4D Molecular Therapeutic For: Jul 09 Filed by: Kirn David

Tue, 14 Jul 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260714/26768979.html

Form 4 4D Molecular Therapeutic For: Jul 09 Filed by: Kirn David

Tue, 14 Jul 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260714/26768979.html

Form 144 4D Molecular Therapeutic Filed by: Kirn David

Fri, 10 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260710/26757848.html

Form 144 4D Molecular Therapeutic Filed by: Kirn David

Fri, 10 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260710/26757848.html

Form 144 4D Molecular Therapeutic Filed by: Kirn David

Thu, 09 Jul 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260709/26753974.html

Form 144 4D Molecular Therapeutic Filed by: Kirn David

Thu, 09 Jul 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260709/26753974.html

Form 4 4D Molecular Therapeutic For: Jun 30 Filed by: Bizily Scott

Thu, 02 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260702/26727683.html

Form 4 4D Molecular Therapeutic For: Jun 30 Filed by: Bizily Scott

Thu, 02 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260702/26727683.html

Form 144 4D Molecular Therapeutic Filed by: Bizily Scott

Tue, 30 Jun 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260630/26714275.html

Form 144 4D Molecular Therapeutic Filed by: Bizily Scott

Tue, 30 Jun 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260630/26714275.html

H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)

Tue, 30 Jun 2026 06:44:47 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $36.00 price target on 4D Molecular Therapeutics (NASDAQ: FDMT).

The analyst commented: "In the context of the continually evolving retinal therapeutics landscape most recently discussed here, we are greatly encouraged to see the announced pivotal Phase 3 4FRONT-2 global trial enrollment completed approximately 4-months ahead of initial company projections. This follows FDMT’s pivotal 4D-150 gene therapy Phase 3 4FRONT-1 North American trial (100% treatment naïve) completing enrollment, now joined by the parallel Phase 3 4FRONT-2 global trial (60% treatment naïve, 40% previously treated and diagnosed within 6-months). As we watch the

Form 8-K 4D Molecular Therapeutic For: Jun 24

Mon, 29 Jun 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260629/26702443.html

Form 8-K 4D Molecular Therapeutic For: Jun 24

Mon, 29 Jun 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260629/26702443.html

4DMT secures $200M credit facility with Hercules Capital

Mon, 29 Jun 2026 08:00:49 -0400

4D Molecular Therapeutics (Nasdaq: FDMT) has entered into a credit facility agreement with Hercules Capital (NYSE: HTGC) for up to $200 million, according to a company press release.

Under the terms of the agreement, 4DMT drew an initial $20 million at closing. An additional $30 million is available at the company's option through June 15, 2027. A further $100 million becomes available upon achievement of certain unspecified milestones, with the remaining $50 million subject to final lender approval.

The company reported cash, cash equivalents, and marketable securities of $458 million as of March 31, 2026, excluding the new credit facility. 4DMT said

4DMT secures $200M credit facility with Hercules Capital

Mon, 29 Jun 2026 08:00:49 -0400

4D Molecular Therapeutics (Nasdaq: FDMT) has entered into a credit facility agreement with Hercules Capital (NYSE: HTGC) for up to $200 million, according to a company press release.

The company reported cash, cash equivalents, and marketable securities of $458 million as of March 31, 2026, excluding the new credit facility. 4DMT said

Vivani Medical adds August Moretti to board as Dean Baker retires

Fri, 26 Jun 2026 07:30:33 -0400